. Hepatobase and . Hepatoweb, Dr Mennecier D. Lecarrefour « de l'Hépatologie, de la Gastro-Entérologie et de l'Alcoologie

P. Marcellin, S. Péquignot, E. Delarocque-astagneau, N. Ganne, P. Hillon et al., 468 Evidence for high rates of HCV and HBV related mortality in FRANCE: A large-scale national survey, Journal of Hepatology, vol.44, issue.468, pp.2-174, 2006.
DOI : 10.1016/S0168-8278(06)80468-X

O. Mir, Vaccination coverage among medical residents in Paris, France, Clinical Microbiology and Infection, vol.18, issue.5, 2012.
DOI : 10.1111/j.1469-0691.2012.03788.x

URL : http://doi.org/10.1111/j.1469-0691.2012.03788.x

B. Blumberg, POLYMORPHISMS OF THE SERUM PROTEINS AND THE DEVELOPMENT OF ISO-PRECIPITINS IN TRANSFUSED PATIENTS, Bull N Y Acad Med, vol.40, pp.377-86, 1964.
DOI : 10.1142/9789812813688_0017

H. Alter and B. Blumberg, « Further studies on a "new" human isoprecipitin system (Australia antigen), Blood, vol.27, issue.3, pp.297-309, 1966.

P. Maupas, A. Goudeau, P. Coursaget, J. Drucker, and P. Bagros, IMMUNISATION AGAINST HEPATITIS B IN MAN, The Lancet, vol.307, issue.7974, pp.1367-70, 1976.
DOI : 10.1016/S0140-6736(76)93023-3

F. Barin, M. André, A. Goudeau, P. Coursaget, and P. Maupas, « Large scale purification of hepatitis B surface antigen (HBsAg), Ann Microbiol (Paris), vol.129, issue.1, pp.87-100, 1978.

J. Chiron, P. Coursaget, B. Yvonnet, and P. Maupas, Inventeur du vaccin contre l'hépatite B », Revue d'histoire de la pharmacie, pp.279-292, 1998.
DOI : 10.3406/pharm.1998.4655

F. Du-genhevac and B. , Vascularites postvaccinales : à propos de trois observations, Rev. Med. Interne, vol.32, issue.22 2, pp.172-176, 2001.

R. Gherardi, M. Coquet, C. P. Authier, J. Laforet, P. Belec et al., Macrophagic myofasciitis: an emerging entity, The Lancet, vol.352, issue.9125, pp.347-52, 1998.
DOI : 10.1016/S0140-6736(98)02326-5

P. Cherin, Macrophagic myofasciitis in a differential diagnosis of inflammatory myopathies, European Congress of Rheumatology (EULAR), 2005.

K. Gruis, J. Teener, and M. Blaivas, Pediatric macrophagic myofasciitis associated with motor delay, Clin Neuropathol, vol.25, issue.4, pp.172-181, 2006.

P. Cherin, E. Konofal, A. Teixeira, C. Chantalat-auger, I. Arnulf et al., P450 Sleep disorders in macrophagic myofasciitis, European Journal of Internal Medicine, vol.14, 2003.
DOI : 10.1016/S0953-6205(03)91713-4

P. Cherin, C. De-jaeger, A. Teixeira, C. Chantalat-auger, and . Le-germmad, P452 Neurocognitive involvement in macrophagic myofasciitis: a prospective study, European Journal of Internal Medicine, vol.14, 2003.
DOI : 10.1016/S0953-6205(03)91715-8

J. Authier, C. P. Creange, A. Bonnotte, B. Ferrer, X. Abdelmoumni et al., Central nervous system disease in patients with macrophagic myofasciitis, Brain, vol.124, issue.5, pp.974-83, 2001.
DOI : 10.1093/brain/124.5.974

R. Gherardi, M. Coquet, C. P. Belec, L. , M. Ph et al., Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle, Brain, vol.124, issue.9, pp.1821-1852, 2001.
DOI : 10.1093/brain/124.9.1821

Y. Mikaeloff, G. Caridade, and S. Suissa, Marc Tardieu « Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood, BEH, pp.16-17176, 2009.

J. Zuckerman and «. , Vaccination against hepatitis A and B: developments, deployment and delusions, Current Opinion in Infectious Diseases, vol.19, issue.5, pp.456-465, 2006.
DOI : 10.1097/01.qco.0000244051.23511.09

A. Martín-ancel, M. Casas, and B. Bonet, Abstract, Infection Control & Hospital Epidemiology, vol.37, issue.07, pp.611-614, 2004.
DOI : 10.1046/j.1537-2995.1995.35695288765.x

S. Krugman, M. Davidson, and «. Hepatitis, vaccine: prospects for duration of immunity, J Biol Med, vol.60, issue.4, pp.339-333

K. Petersen, L. Bulkow, B. Mcmahon, C. Zanis, M. Getty et al., Duration of Hepatitis B Immunity in Low Risk Children Receiving Hepatitis B Vaccinations From Birth, The Pediatric Infectious Disease Journal, vol.23, issue.7, pp.655-650, 2004.
DOI : 10.1097/01.inf.0000130952.96259.fd

P. Van-damme and K. Van-herck, A review of the long-term protection after hepatitis A and B vaccination, Travel Medicine and Infectious Disease, vol.5, issue.2, pp.84-79, 2007.
DOI : 10.1016/j.tmaid.2006.04.004

N. Pasricha, U. Datta, Y. Chawla, S. Singh, S. Arora et al., Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine, BMC Infectious Diseases, vol.42, issue.1, p.65, 2006.
DOI : 10.1016/j.jhep.2005.03.003

A. Rosman, P. Basu, K. Galvin, and C. Lieber, Efficacy of a High and Accelerated Dose of Hepatitis B Vaccine in Alcoholic Patients, The American Journal of Medicine, vol.103, issue.3, pp.22-217, 1997.
DOI : 10.1016/S0002-9343(97)00132-0

A. Roome, S. Walsh, M. Cartter, and J. Hadler, « Hepatitis B vaccine responsiveness in Connecticut public safety personnel, JAMA, vol.270, pp.24-2931, 1993.

C. Stratégies-de-dépistage-biologique-des-hépatites-b, Recommandation en santé publique, HAS mars 2011 et Améliorer le dépistage des hépatites virales B et C, 2011.